PPARA and metabolic dysfunction-associated steatohepatitis: Overall, while some PPAR agonists show potential for treating MASLD/MASH, their varied pharmacokinetic and pharmacodynamic properties require individualized clinical evaluations to ensure their efficacy and safety.